Moderna Stock Price Has Collapsed 87% From Its Peak — Now What?

Looking at a stock chart and realizing you’re staring at the ruins of something that was once hailed as a miracle can cause a certain kind of vertigo. In the summer of 2021, Moderna’s stock price reached almost $500 per share, an almost unbelievable moment. A company that had never released a product prior to the pandemic was suddenly valued at over $180 billion, and its name became synonymous with mRNA possibility and scientific speed. MRNA is currently trading at about $51. The gap between those two figures reveals a narrative that combines elements of market psychology, science, and the more difficult-to-identify slow, grinding recalibration that follows extraordinary expectations.

Moderna’s stock, which is currently trading at about $51 as of April 9, 2026, has a market capitalization of slightly over $20 billion, which is still significant but feels almost insignificant given the scope of the company’s endeavors. Revenue for Q4 2025 was $678 million, down almost 30% from the previous year. This figure supports what most investors already knew: the COVID vaccine cycle in the US is over. U.S. revenue was $1.2 billion last year, and management anticipates a further decline to about $1 billion in 2026. That represents a 20% drop in the company’s home market from the previous year. It is difficult to read for anyone who owns the stock.

Moderna Inc (NASDAQ: MRNA) — Company Profile

The difference between the short-term revenue picture and the longer-range pipeline is what makes Moderna’s situation truly complex and, depending on your perspective, genuinely fascinating. The drop in revenue has been observed by hedge funds. With 17.8% of its float sold short, MRNA currently has the highest short interest of any S&P 500 stock, according to the equity team at Bank of America. That figure is impressive. When they see a clear and obvious thesis—that is, that the stock is still not cheap by conventional measures, the COVID tailwinds are gone, and cash is burning—short sellers often pour in. The reasoning is sound. It might simply be lacking.

Speaking at a healthcare conference in March, Moderna’s CFO Jamey Mock publicly acknowledged the challenges facing domestic revenue. It didn’t have any spin. However, things are different on a global scale. Through multi-year government contracts with the UK, Canada, and Australia, the company brought in $700 million from outside the US in 2025. By 2026, that amount is predicted to reach $1 billion. Europe, on the other hand, is still essentially shut out of the $1.8 billion respiratory vaccine market until later this year due to a competitor’s contract. For its combined COVID and flu vaccine in Europe, Moderna recently received a favorable regulatory committee opinion. The timing is not coincidental. Moderna is standing right outside that door, which is about to open.

The story of the cancer vaccine is difficult to quantify, but it cannot be disregarded. Developed in tandem with Merck and its immunotherapy Keytruda, Intismeran is currently undergoing a Phase III trial for adjuvant melanoma, which is reportedly one of the fastest-enrolling late-stage oncology studies ever carried out. According to phase II data, the hazard ratio for recurrence-free survival at three years was 0.51, and this value persisted for five years. Analysts say the commercial case is still strong even if Phase III produces a more modest hazard ratio of 0.75. Additionally, Moderna is conducting eight concurrent late-stage cancer studies related to lung, bladder, kidney, and melanoma. Its sheer scope is either an extremely costly diversion or a sign of serious ambition. Most likely a combination of the two.

Observing all of this, it seems as though the market has effectively determined that Moderna is a COVID story and that COVID stories are over. In 2023 and 2024, that framing might have been accurate. Now it’s less evidently true. The U.S. PDUFA date for the stand-alone flu shot is August 5 of this year, which indicates that an approval decision will be made shortly. Management has called it a multibillion-dollar opportunity, and if approved, it would be Moderna’s first commercially significant non-COVID product. The effectiveness of an mRNA flu vaccine in comparison to the well-established egg-based substitutes that are currently found in every pharmacy cooler in America will determine whether or not that wording turns out to be accurate.

With $8.1 billion in cash at the end of 2025, the company had enough cash on hand to finance the pipeline through several trial readouts without the need for an urgent capital raise. In 2025, cost reductions surpassed the $1 billion target. With what remains, Moderna is not careless. That might be more important than what the short sellers are pricing in. If catalysts take longer than anticipated, it’s also possible that the bears are correct and the stock returns to the low $40s.

The current share price is below the average analyst target of $43.80, which is an odd and a little unsettling situation because most stocks trade below rather than above their consensus targets. This inversion implies that either the recent rally has outpaced the fundamentals or the analysts are being overly cautious. Determining which necessitates determining your belief in the pipeline. And in the end, that is the only question that really counts.